SAPTALIS PHARMS
PharmaSAPTALIS PHARMS is a pharmaceutical company focused on Infectious Disease, Immunology. Key products include LIKMEZ.
SAPTALIS PHARMS's Key Drugs
SAPTALIS PHARMS's core commercial portfolio centers on LIKMEZ, spanning Infectious Disease and Immunology — its most strategically important drugs approved in the last 15 years.
SAPTALIS PHARMS's Recent FDA Approvals
New NDA/BLA approvals for SAPTALIS PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
SAPTALIS PHARMS's Therapeutic Areas
SAPTALIS PHARMS's approved drugs and pipeline span 2 therapeutic areas, led by Infectious Disease and Immunology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SAPTALIS PHARMS's Top Competitors
SAPTALIS PHARMS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SAPTALIS PHARMS Pipeline Snapshot
Active clinical trials for SAPTALIS PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • LIKMEZ leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 1961-06-23
- Latest
- 2026-06-11
- Applications
- 9